A synopsis of current care of thalassaemia major patients in Hong Kong by Ha, SY et al.
Title A synopsis of current care of thalassaemia major patients inHong Kong
Author(s)
Au, WY; Lee, V; Lau, CW; Yau, J; Chan, D; Chan, EYT; Cheung,
WWW; Ha, SY; Kho, B; Lee, CY; Li, RCH; Li, CK; Lin, SY; Ling,
ASC; Mak, V; Sun, L; Wong, KHF; Wong, R; Yuen, HL
Citation Hong Kong Medical Journal, 2011, v. 17 n. 4, p. 261-266
Issued Date 2011
URL http://hdl.handle.net/10722/152728
Rights Hong Kong Medical Journal. Copyright © Hong Kong Academyof Medicine Press.
	 Hong	Kong	Med	J		Vol	17	No	4	#	August	2011	#		www.hkmj.org	 261
 Objective To provide a synopsis of current thalassaemia major patient care 
in Hong Kong.
 Design Retrospective study. 
 Setting All haematology units of the Hospital Authority in Hong Kong.
 Patients All patients with thalassaemia major with regular transfusion. 
 Results To date, there were 363 thalassaemia major patients under 
the care of the Hospital Authority. Prenatal diagnosis has 
helped to reduce the number of indigenous new cases, but 
in recent years immigrant cases are appearing. The patients 
have a mean age of 23 (range, 1-52) years, and 78% of them 
are adults. In 2009, they received 18 782 units of blood. This 
accounted for 9.5% of all blood consumption from the Hong 
Kong Red Cross. In the past, cardiac iron overload was the 
major cause of death (65%) and few patients survived beyond 
the age of 45 years. The availability of cardiac iron assessment 
by magnetic resonance imaging (T2* MRI) to direct the use 
of oral deferiprone chelation has reduced the prevalence of 
heart failure and cardiac haemosiderosis, which should reduce 
mortality and improve life expectancy. 
 Conclusion The future for thalassaemia care in Hong Kong is bright. With 
better transfusion and chelation, it should be possible to avoid 
growth and endocrine deficiencies in younger patients.
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Introduction
Thalassaemia is common in Southern China. In Hong Kong, 3% of the population carries a 
β-globin thalassaemia gene mutation.1 Carriage of two β-thalassaemia mutations results in 
moderate-to-severe anaemia from infancy. Thalassaemia major (TM) refers to the condition 
of lifelong transfusion dependence. With improved public education, antenatal care 
and prenatal diagnosis,2 the incidence of newborn TM cases in Hong Kong has dropped 
dramatically. There are currently 363 TM patients (long-term regular transfusion over 6 
times per year) under the care of the Hospital Authority. In this article, we review the 
comprehensive care available to these patients. Patients who have successfully received 
haematopoietic stem cell transplantation (HSCT) and those with milder thalassaemia and 
other congenital dyserythropoietic or transfusion-dependent conditions are not included 
in the current review.
Demography
Both paediatric as well as adult medical units take care of TM cases according to their 
age. Their age and gender distribution are shown in Figure 1a, and the population-based 
New knowledge added by this study
• Systematic data on the population-based prevalence of thalassaemia major in Hong Kong are 
provided.
• Clinically significant improvements in morbidity and mortality are achievable based on 
magnetic resonance imaging–directed oral chelation therapy.
Implications for clinical practice or policy
• Transfusion and chelation resources have to be planned for current thalassaemia major cases, 
with the expectation of near-normal health and life expectancy.
• New cases of thalassaemia major continue to appear in Hong Kong, so some patients did not 
benefit from the availability of universal prenatal screening.
CME
		#		Au	et	al	#
262	 Hong	Kong	Med	J		Vol	17	No	4	#	August	2011	#		www.hkmj.org
from HSCT. There is a rapid dropoff in patient number 
beyond the age of 40 years, mainly due to premature 
cardiac deaths. However, with better iron assessment 
and chelation, future life expectancy of TM patients 
is expected to approach that of the background 
population. Presently, 78% of thalassaemia patients 
are already adults, while only 22% are below the age 
of 18 years. Hence, it is hoped that thalassaemia care 
will gradually shift from paediatric to adult (and later 
geriatric) medicine. 
Transfusion
Safe and free red cell transfusion is available for 
all patients in Hong Kong. Due to their transfusion 
habits however, the pre-transfusion haemoglobin 
level of these patients ranges from 55 to 111 g/L 
with a median of 92 g/L. A total of 132 (36%) of the 
patients had undergone splenectomy (age range, 
5-56; median, 30 years). In 2009, the total blood 
consumption was 18 782 units, which accounts for 
9.5% of all red cells collected in Hong Kong during 
that period. Pre-storage filtered, phenotype-matched 
blood units are pre-arranged for all patients ahead 
of their scheduled transfusions. The prevalence of 
allo-antibody carriage in Hong Kong TM cases is low.4 
However, lifelong regular transfusion (and cross-
matching beforehand) imposes a huge burden on 
the social life of these patients.
Iron overload
With free transfusions, iron overload and organ 
failure (particularly cardiac iron overload and heart 
	 目的	 提供現時香港重型地中海貧血患者的治療概覽。
	 設計	 回顧研究。 
	 安排	 香港醫院管理局轄下醫院的血液學部門。
	 患者	 須定期輸血的重型地中海貧血患者。 
	 結果	 迄今共363名重型地中海貧血患者於醫院管理局轄下
醫院接受治療。在產前診斷有助減少遺傳性新症的同
時，近年開始出現來自內地新移民的病例。這363名
患者的平均年齡為23歲（介乎1-52歲），78%為成年
  人。他們於2009年輸血共18 782個單位，佔香港紅十字
  會全年輸血量9.5%。過往，心臟過量鐵質積聚是導
致死亡的主因（65%），只有少數患者的壽命超過45
歲。透過磁共振成像（T2*）評估心臟鐵質存量，以
指引口服除鐵藥物的螯合作用，有助減低心臟衰竭和
心臟血黃素沉積病的發病率，從而減低一定程度的死
亡率和延長患者壽命。 
	 結論	 地中海貧血治療的發展前景是樂觀的。隨着更佳的滲
流和螯合治療，有望改善年青患者的發育和內分泌缺
乏問題。
香港重型地中海貧血患者的治療現況概覽
prevalence is illustrated in Figure 1b. They included 
178 male and 185 female patients, with a mean age 
of 23 years (range, 1-52 years). Several factors affect 
the age distribution. The number of new cases has 
dropped from a median of 16 per year to around 
3 per year, but has recently increased again due 
to Mainland China migrants and cross-border 
newbirths.3 Some paediatric cases leave the cohort 
due to successful (or regrettably, fatal) outcomes 
FIG 1.  Thalassaemia major: (a) number of cases and (b) population-based prevalence in different age-groups
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failure) become the leading cause of death. Parenteral 
deferoxamine was available in Hong Kong in 1970s 
and significantly reduced patient mortality.5 To gauge 
chelation adequacy and as a surrogate for heart iron, 
serum ferritin is the cheapest and most convenient 
means of monitoring. It is checked quarterly in the 
clinics, and the current median ferritin level among 
all TM cases in Hong Kong is 3664 (range, 235- 
51 789; normal range, 52-738) pmol/L. Unfortunately, 
serum ferritin level fluctuates with inflammation, 
hepatitis and the time of the day. It also correlates 
better with liver rather than cardiac iron.6 In the 1990s, 
liver iron was commonly adopted as surrogate marker 
of cardiac iron and chelation adequacy. In Hong 
Kong, it was only assessed by liver biopsies, which 
were invasive, and require complex biochemical 
analysis with limited reproducibility.7 Liver biopsies 
are now obsolete in TM cases, except for histological 
assessments of viral hepatitis.7 Neither ferritin nor 
liver iron show significant correlations with cardiac 
iron as measured by magnetic resonance imaging 
(MRI).8 The latter is the only independent predictor 
of heart failure and cardiac death.9
 The development of a standardised T2* 
MRI assessment of cardiac iron was a landmark in 
thalassaemia management. A lower MRI reading 
in milliseconds (ms) indicates more cardiac iron 
(normal, >20 ms; high risk of death, <10 ms).9 As 
part of an international effort, the MRI scanner in 
Prince of Wales Hospital was calibrated against the 
international standard in 2006.10 Later, all TM cases in 
Hong Kong were offered scanning under the auspices 
of the Children’s Thalassemia Foundation (HKCTF). 
Among 180 adult patients scanned and reported, the 
median T2* MRI level of the heart was 19.3 (range, 
3.3-63.5) ms and that of liver was 3.1 (range, 1.0-31.8; 
normal, <6.3) ms. Inadequate chelation was therefore 
common, with only half of patients having a normal 
cardiac T2*; and 26% and 14% of cases had severely 
abnormal MRI cardiac T2* (<10 ms) and liver (<1.6 
ms) T2* levels, respectively.11 Considerable iron 
accumulation was also demonstrated in endocrine 
organs. Both heart and endocrine haemosiderosis 
correlated with organ dysfunction.12,13 Clearly, 
subcutaneous deferoxamine-based chelation did 
not completely prevent cardiac haemosiderosis and 
premature mortality. Nonetheless, in young patients 
and for historical reasons it was still the first-line 
chelation therapy. 
 Oral deferiprone can reduce cardiac iron, 
leading to prevention and reversal of heart failure.14 
In Hong Kong, the drug was licensed in 2005.7 The 
use of oral deferiprone (either as monotherapy 
or in combination with nocturnal subcutaneous 
deferoxamine)15 resulted in a dramatic reduction 
in cardiac haemosiderosis and ferritin levels. With 
the advent of combination therapy, 13% of Hong 
Kong TM cases now have ferritin levels within 
normal range. Epidemiological experience from 
Italy, England, and Cyprus suggests that MRI-
directed deferiprone therapy could reduce cardiac 
iron and TM mortality.16-18 This was supported by 
our local data.15 A 3-year reassessment MRI (HKCTF 
scheme) showed improvement among all 84 of the 
90 previously poorly chelated adult patients (2 died 
of heart failure, 4 refused re-scan). The percentage 
of very poor T2* MRIs (<10 ms) fell by half. However, 
agranulocytosis is a life-threatening side-effect of 
deferiprone, for which reason seven TM patients had 
to stop treatment. A third chelator, oral deferasirox 
was introduced in 2008 after extensive safety and 
efficacy testing.19,20 Deferasirox monotherapy showed 
promise in reducing ferritin levels as well as liver and 
heart iron after prolonged treatment.21 However, 
the cost (up to 10 times that of deferiprone or 
deferoxamine) remains prohibitive, and it is contra-
indicated in patients with renal impairment. Survival 
benefit data are also pending. It is currently used in 
Hong Kong in very young patients (age <6 years), 
poorly chelated patients with contra-indication to 
deferiprone, as well as those who self-finance the 
treatment or enter clinical trials. At present chelation 
for TM cases in Hong Kong involves subcutaneous 
deferoxamine (30%), oral deferiprone (17%), 
combination deferiprone and deferoxamine therapy 
(48%), and oral deferasirox (n=5%). 
Organ damage
Since iron deposit and organ damage is cumulative, 
in TM population the prevalence of some organ 
failures increases with age. Cardiac failure is the most 
important cause of death in TM. A low cardiac T2* 
MRI is the only predictor for future heart failure and 
cardiac deaths.22 Among the 180 patients surveyed 
in 2006, the prevalence of low ejection fraction (EF) 
[<55%] was 19%, while 34% of the cases also had a 
history of heart failure.12 Among the 90 patients with 
abnormal T2*MRIs (<20 ms), the median EF was only 
59%. With aggressive chelation, this improved to 68% 
(P<0.001). Only eight patients still had EFs below 55%, 
seven of whom showed an improving trend. Two 
patients died of heart failure (cardiac T2*MRIs being 
3.5 ms and 4.3 ms) shortly after their first assessment. 
 The prevalence of endocrine failure was also 
high in this population. Diabetes mellitus occurs in 
up to 25% of adults with TM and is rapidly emerging 
as the most important cause of morbidity.11 Such a 
high prevalence may reflect inadequate chelation at 
younger ages, since established pancreatic damage 
is less reversible than cardiac damage, even with 
aggressive chelation. Hypogonadism is prevalent 
among older patients and half of all adult male and 
female patients are on hormone replacements. 
Younger patients, however, had normal gonadal 
function, weight and stature, and were physically 
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indistinguishable from the normal population. 
Recently, two Hong Kong women with TM 
successfully gave birth. Other endocrinopathies such 
as hypothyroidism (20%) and hypoparathyroidism 
(16%) were less common.11 
 Osteoporosis is highly prevalent in these 
patients. In a dual-energy X-ray absorptiometry scan 
screening of 62 adult TM cases, the median vertebral 
Z score was -1.93 (range, -0.13 to -3.84), while the 
median hip Z score was -1.79 (range, -0.32 to -3.87).23 
All Z scores fell with age indicating ongoing bone 
loss. Osteoporosis and osteopenia were diagnosed 
in 29% and 37% of all Queen Mary Hospital TM cases, 
respectively; similar findings were also reported 
from Tuen Mun and Prince of Wales hospitals.23 
Among multiple risk factors, reduced vitamin D 
levels and hypogonadism are correctable causes of 
bone loss.24 Supplements of calcium and vitamin D 
are recommended. For patients with osteoporosis, 
additional treatments with standard weekly or 
monthly bisphosphonates are useful.25 Strontium has 
not been used to treat local TM patients. 
Infection
With the implementation of nucleic acid testing for 
viral DNA, the risk of transfusion-related infection for 
blood products in Hong Kong has been reduced to 1 
in 5 million for hepatitis C virus (HCV), 1 in 1 million 
for human immunodeficiency virus (HIV), and 1 in 
11 000 for hepatitis B virus (HBV) [written 
communication, CK Lee, Hong Kong Red Cross 
Blood Transfusion Service]. A total of 59 TM patients 
tested positive for HCV antibody carriage (age range, 
13-49 years). It is known that up to 30% of HCV 
antibody carriers may be non-viraemic,26 and have 
had no evidence of hepatitis on biopsy.27 For non-
viraemic TM patients, HCV antiviral treatment is not 
necessary, but monitoring for HCV recrudescence 
and liver cancer is advisable.28 In young Hong Kong 
TM patients with HCV viraemia and active hepatitis, 
the response to a combination treatment of ribavirin 
and pegylated interferon was good.29 Since 1999, no 
more transfusion-related HCV has been reported 
among TM patients in Hong Kong. Only six patients 
(age range, 22-49 years) were HBV surface antigen 
* Secular years from 1995 to 2009 
† HSCT denotes haematopoietic stem cell transplantation
TABLE. Numbers of thalassaemia major patients in Hong Kong succumbing to various causes
Year* Heart failure HSCT† Infection Renal failure Cancer Suicide Stroke Total (all 
causes)
 95-97 7 4 1 0 1 0 0 13
 98-00 8 2 3 0 0 0 0 13
 01-03 7 1 0 1 1 0 0 10
 04-06 4 0 1 1 0 0 1 7
 07-09 3 0 0 1 0 1 0 5
Total 29 (61%) 7 (15%) 5 (10%) 3 (6%) 2 (4%) 1 (2%) 1 (2%) 48
FIG 2. Deaths in thalassaemia major patients in Hong Kong: 1996 to 2009
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(HBsAg) carriers. No new TM HBV carriers were 
reported since the advent of universal vaccination in 
Hong Kong lifebirths in 1988. The HBsAg carriage rate 
was 2.7% in TM cases aged older than 22 years. This 
was consistent with the background prevalence rate, 
and unlikely to be related to local blood transfusions. 
There was one reported TM case of transfusion-
related HIV. This occurred prior to the era of 
screening blood products by nucleic acid testing.30 
 There was a considerable frequency of 
Klebsiella sepsis in deferoxamine-treated TM patients 
in Hong Kong.31 Campylobacter infection has also 
been reported. Both are ferrophilic organisms and 
can cause life-threatening infections and abscesses. 
In TM patients, there is also an increased prevalence 
of haemolytic anaemia-related gallstones, acute 
cholecystitis, cholangitis, and even liver abscesses.32 
Yersinia infection was commonly reported in Italian 
and Greek TM cases, but is seldom encountered 
locally.
Mortality
A survey in 1999 showed that heart failure, HSCT, and 
sepsis were the three leading causes of mortality in 
TM patients.5 An updated survey of mortality from 
1996 to 2009 revealed that heart failure (61%), HSCT 
(15%), and sepsis (10%) remained the main causes 
of death (Table). The risk-benefit ratio of HSCT 
in young thalassaemia patients is debatable, and 
depends on donor availability, age, iron load, organ 
damage, and HSCT expertise.33 Encouragingly, in TM 
patients there has been a steady decline in the crude 
incidence of death (Fig 2). There is also suggestion 
that better chelation, HSCT, and infection control 
has reduced the traditional causes of death. With 
increasing age, other causes of mortality (eg renal 
failure secondary to diabetes mellitus) may begin to 
emerge.
Social challenges and conclusions
Reduced life expectancy, the need for regular blood- 
taking follow-ups, and daily medications (including 
injections), as well as retardation in growth and 
sexual developments (particularly in earlier cohorts) 
impose huge personal challenges to TM patients 
and their families. With improved treatment, the 
external appearance of younger TM cases can be 
indistinguishable from normal children and adults. 
Historically, disruption to schooling and employment 
could be prohibitive. Such difficulties can be 
alleviated by increasing weekend and evening cross-
matching and transfusions. Today, many TM patients 
in Hong Kong are able to enjoy a full education, 
career, marriage and family life. This is a tribute to the 
0.2 million annual blood donors in Hong Kong, our 
safe blood supply, the efficiency of our public hospital 
care system, and the dedication of the numerous 
medical and nursing colleagues who provide lifelong 
care for affected patients. With increasing age, 
more TM patients are transferred to adult units. A 
redistribution of resources, plus a readjustment of 
patient and parent expectations, has to follow. Novel 
approaches such as the establishment of special 
transfusion centres need to be explored. Medical 
professionals will continue to work closely with the 
patient and parent groups to achieve a continuously 
improving quality of life for these individuals.
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